EMA Clarifies CV Safety Analysis of New Heart, Metabolic Drugs 

Drug Industry Daily
A A
Sponsors of new drugs to treat cardiovascular and metabolic diseases should use a composite of all major cardiovascular events as the primary endpoint in studies to establish CV risk, the European Medicines Agency says.

To View This Article:

Login

Subscribe To Drug Industry Daily